Sen. Grassley’s letter to Amgen regarding FDA access to study data and rebate payments and discounts to physicians
Via Electronic Transmission
Mr. Kevin Sharer Chief Executive Officer Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799
Dear Mr. Sharer:
The United States Senate Committee on Finance (Committee) has jurisdiction over the Medicare and Medicaid programs and, accordingly, a responsibility to the more than 80 million Americans who receive health care coverage under those programs to oversee the proper administration of the programs, including the payment for prescription drugs regulated by the Food and Drug Administration (FDA).
Thank you for the briefing that Amgen Inc. (Amgen) provided my Committee staff on May 24, 2007, in response to my letter to you dated May 16, 2007. Additionally, thank you for your cooperation with the Committee’s request for information related to erythropoiesis-stimulating agents (ESAs).
###
Next Article Previous Article
Recent News
- Wyden, Sanders Demand Answers from Trump Administration Over Mass Layoffs that Threaten the Wellbeing of Children and Families
- Wyden, Sanders Demand Answers from Trump Administration Over Mass Layoffs that Threaten the Wellbeing of Children and Families
- Wyden, Cortez Masto Call for Criminal Investigation into Evidence of Fraud by Promoters Affiliated with IRS Nominee Billy Long
- Wyden Statement on Social Security Using Death Master List to Revoke Social Security Numbers
- Wyden, Whitehouse Lead Colleagues in Demanding Answers on DOGE’s Access to the Sensitive National Child Support Database